Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
826 hot topic(s) found with the query "Precision medicine"

A Group-Mediated Approach to Precision Medicine-Social Identification, Prevention, and Treatment.
Beauchamp Mark R et al. JAMA psychiatry 2020 Feb (Posted: Feb-27-2020 7AM)

Precision medicine mostly focuses on genomics. There is emerging interest to screen for social risk factors in clinical settings, such as unemployment, food insecurity, partner violence, housing quality, and difficulty affording medication.


Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
Emdin Connor A et al. Circulation. Genomic and precision medicine 2020 Feb (1) e002767 (Posted: Feb-25-2020 9AM)


New Precision Medicine Program to Study Role of Genomics in Disease
J Kent, Health IT Analytics, February 13, 2020 (Posted: Feb-17-2020 10AM)


NHGRI establishes new intramural precision health research program
NIH, February 2020 Brand (Posted: Feb-17-2020 10AM)

The National Human Genome Research Institute has announced plans to establish a new precision health research program within its Division of Intramural Research. The goal of the program is to develop and evaluate next-generation healthcare that uses cutting-edge genomic and informatic tools to improve the diagnosis, treatment and prevention of disease.


The role of public health in precision medicine
Interview with K Gebbo, All of Us, February 2020 (Posted: Feb-17-2020 10AM)

A lot of people have viewed this as a genetic study but from my perspective, it is not; it is a population study and we have both survey data and physical measurements, too. So, there are a number of other characteristics of this research program that I want to make sure people are aware of.


Bringing Personalized Medicine to Precision Medicine in Gastroesophageal Cancer
J Chao et al, JAMA Network Open, February 14, 2020 (Posted: Feb-17-2020 10AM)


An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice-A Review
M Rainone et al, JAMA Oncology, February 13, 2020 (Posted: Feb-14-2020 8AM)

With increasing evidence and slow improvement of outcomes, PDAC has entered the era of precision medicine. Germline mutations have been identified in key genes with an aggregate frequency of 3.8% to 9.7%, several of which are therapeutically actionable with platinum, PARPi, and checkpoint inhibitor therapy.


A 2020 Reality Check on the Public Health Impact of Cancer Genomics and Precision Medicine
Khoury MJ et al, CDC BLog, February 10, 2020 Brand (Posted: Feb-11-2020 9AM)

Precision oncology has had some major successes… And yet, the overall effect of precision medicine on care for patients with cancer has been modest. Nonetheless, it is important for public health to explore using novel and more precise approaches to monitor cancer burden, and implement proven cancer control goals especially in hard to reach populations


The application of big data to cardiovascular disease: paths to precision medicine.
Leopold Jane A et al. The Journal of clinical investigation 2020 Jan (1) 29-38 (Posted: Feb-07-2020 8AM)


A precision medicine–based strategy for a severe adverse drug reaction
MR Mack et al, Nature Medicine, February 3, 2020 (Posted: Feb-04-2020 9AM)


Contributions of the UK biobank high impact papers in the era of precision medicine.
Glynn Peter et al. European journal of epidemiology 2020 Jan (Posted: Feb-02-2020 9AM)

In this assessment of the first 7 years of the UK Biobank and first 4 years of genetic data availability, the majority of high impact UK Biobank studies either replicated known associations or generated novel associations without clinically relevant improvements in risk prediction, screening, or treatment.


Addressing Disparities Will Advance Genomics, Precision Medicine,
by Jessica Kent, Health It Analytics, January 27, 2020 (Posted: Jan-29-2020 8AM)


Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging.
Hou Ying-Chen Claire et al. Proceedings of the National Academy of Sciences of the United States of America 2020 Jan (Posted: Jan-29-2020 8AM)

Genome sequencing has established clinical utility for rare disease diagnosis. While increasing numbers of individuals have undergone elective genome sequencing, a comprehensive study surveying genome-wide disease-associated genes in adults with deep phenotyping has not been reported


Reducing the Global Public Health Burden of Familial Hypercholesterolemia: More Work Ahead
MJ Khoury et al, CDC Blog, January 21 2020 Brand (Posted: Jan-21-2020 1PM)

Historically, FH has served as a paradigm for the role of cholesterol in heart disease. FH now also serve as a paradigm for bringing together the strengths of both public health and precision medicine approaches to health. The recommendations of this international group highlight the importance of integrating FH care in health systems with a lifelong approach to care


Molecular profiling for precision cancer therapies.
Malone Eoghan R et al. Genome medicine 2020 Jan (1) 8 (Posted: Jan-17-2020 8AM)

We describe novel molecular characterization strategies beyond tumor DNA sequencing, such as transcriptomics, immunophenotyping, epigenetic profiling, and single-cell analyses. We also review current and potential applications of liquid biopsies to evaluate blood-based biomarkers.


2019 FH Global Summit Presentation Slides
The FH Foundation, January 2020 (Posted: Jan-15-2020 8AM)

The 7th annual FH Global Summit was held in Atlanta, Georgia from October 20-21 and focused on familial hypercholesterolemia as a prototype for precision public health. Over 280 interdisciplinary participants including experts in FH, genomics, precision medicine, as well as healthcare practitioners, individuals with FH and industry attended.


Cancer in sub-Saharan Africa.
Rebbeck Timothy R et al. Science (New York, N.Y.) 2020 01 (6473) 27-28 (Posted: Jan-13-2020 9AM)

The World Economic Forum has initiated a “Leapfrogging with Precision Medicine” initiative that will advance the use of genetics and genomics in cancer prevention and treatment. These and many other institutions and activities have the potential to develop the knowledge and sustainable resources needed to address the cancer burden in Sub Saharan Africa.


Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG
M Porumb et al, Scientific Reports, January 13, 2020 (Posted: Jan-13-2020 9AM)

The current study used personalised medicine approach and Artificial Intelligence (AI) to automatically detect nocturnal hypoglycemia using a few heartbeats of raw ECG signal recorded with non-invasive, wearable devices, in healthy individuals, monitored 24?hours for 14 consecutive days.


In defence of ‘imprecise’ medicine: the benefits of routine treatments for common diseases
The Conversation, January 9, 2020 (Posted: Jan-10-2020 8AM)

It’s hard not to conclude that the nation’s health would be better served if we aspire to be a global leader in the standardization of care for common serious diseases. Let’s not let the current enthusiasm for precision medicine blind us to the benefits of the “imprecise” medicine we know saves millions of lives every year.


How a growing trove of genetic data is informing medical breakthroughs
PBS Newshour, January 9, 2020 (Posted: Jan-10-2020 8AM)

Individualized medicine, in which treatments are customized based on a patient’s unique DNA, is a rising field. Along with an ever-expanding genetic database, it offers tantalizing promise for solving some of medicine's most daunting challenges. But individualized medicine also carries with it questions and risks -- both moral and medical.


Two Threats to Precision Medicine Equity.
Matthew Dayna Bowen et al. Ethnicity & disease 2019 29(Suppl 3) 629-640 (Posted: Jan-02-2020 10AM)


How Can Law Support Development of Genomics and Precision Medicine to Advance Health Equity and Reduce Disparities?
Wolf Susan M et al. Ethnicity & disease 2019 29(Suppl 3) 623-628 (Posted: Jan-02-2020 10AM)

Legal barriers limit use of precision medicine to advance health equity. Problems include inadequate privacy and anti-discrimination protections for research participants, lack of health coverage and funding for follow-up care, failure to use law to ensure access to genomic medicine, and practices by research sponsors that tolerate and entrench disparities.


Pharmacoepidemiology and Big Data Analytics: Challenges and Opportunities when Moving towards Precision Medicine.
Burden Andrea M et al. Chimia 2019 Dec 73(12) 1012-1017 (Posted: Jan-02-2020 9AM)

Pharmacoepidemiology is the study of the safety and effectiveness of medications following market approval. The increased availability and size of healthcare utilization databases allows for the study of rare adverse events, sub-group analyses, and long-term follow-up. These datasets are large, including thousands of patient records spanning multiple years.


Precision medicine has a blind spot: children with cancer
G Nichols, StatNews, December 30, 2019 (Posted: Dec-31-2019 9AM)

Precision medicine, the concept of giving the right treatment to the right patient at the right time, is flourishing in cancer treatment. But there is a blind spot: children are not benefiting enough from the progress we’re making.


The role of race and ethnicity in views toward and participation in genetic studies and precision medicine research in the United States: A systematic review of qualitative and quantitative studies.
Fisher Elena R et al. Molecular genetics & genomic medicine 2019 Dec e1099 (Posted: Dec-30-2019 9AM)

Understanding of genetics was low, yet the majority of participants were willing to participate in genetic research among all populations included in the literature. Recommendations for research included utilizing community-based participatory approaches, evaluating participants' informational needs, incentivizing participation, and providing direct benefits.


Law, Genomic Medicine and Health Equity
Ethnicity and Disease, suppl 2019 (Posted: Dec-16-2019 7AM)

This special supplement to Ethnicity & Disease offers research and commentaries on how law can support the development of genomic and precision medicine in advancing health equity.


Two Threats to Precision Medicine Equity
DB Matthews, Ethnicity and Disease, suppl, 2019 (Posted: Dec-16-2019 7AM)


How Can Law Support Development of Genomics and Precision Medicine to Advance Health Equity and Reduce Disparities?
SM Wolfe et al, Ethnicity and Disease, suppl 2019 (Posted: Dec-16-2019 7AM)

Multiple legal barriers limit broad inclusion in genomic research and the development of precision medicine to advance health equity. Problems include inadequate privacy and anti-discrimination protections for re­search participants, lack of health coverage, failure to use law to ensure access, and practices by research sponsors that entrench disparities.


Looking forward 25 years: the future of medicine
Nature Medicine editorial, December 5, 2019 (Posted: Dec-09-2019 8AM)

We are now on the cusp of an inflection point, where the ‘bigness’ of biomedicine turns into an advantage. We are beginning to see advances towards these goals, in polygenic risk scores, in understanding the cell and modules of action of genes. Going forward, our success in harnessing bigness will rely on our ability to leverage structure, prediction and data scale.


The cost of getting personal
Nature editorial (Posted: Dec-09-2019 8AM)

The recent report of an antisense oligonucleotide therapy designed for only one patient spotlights regulatory, economic and ethical issues that must be grappled with in an era of accelerated development of ‘ultra-personalized’ drugs.


Progress Toward Precision Medicine in Frontline Treatment of Metastatic Renal Cell Carcinoma.
Singla Nirmish et al. JAMA oncology 2019 Dec (Posted: Dec-06-2019 8AM)

As molecular understanding of cancer biology evolves, precision medicine will play a growing role in guiding therapy. This is certainly evident in the case of metastatic renal cell carcinoma (mRCC), which is inherently a heterogeneous tumor type on both clinical and molecular levels.


Personalized, Precision, and <i>N</i>-of-One Medicine: A Clarification of Terminology and Concepts.
Huang Sui et al. Perspectives in biology and medicine 2019 62(4) 617-639 (Posted: Dec-04-2019 9AM)

If response to treatment is different in two patients with the same diagnosis, is this because they suffer from two distinct subtypes of a disease, or because they differ in the physiology that manifests the same disease? Such questions have evoked terms, such as personalized, precision, or "N-of-one" medicine, creating potential for confusion.


Clinical Practice Settings vs Clinical Trials: Is Artificial Intelligence the Answer?
Jampol Lee Merrill et al. JAMA ophthalmology 2019 Nov (Posted: Dec-04-2019 9AM)

Artificial intelligence with deep learning could take real-world patient management forward (for a population or an individual) and may introduce precision medicine into the care of retinal diseases.


Precision public health emerging as a discipline
JK COhen, Modern Healthcare, November 30, 2019 (Posted: Dec-02-2019 8AM)

A new buzzword has crept into the health sciences lexicon: precision public health. By mixing the technical advancements of precision medicine with the goals of public health, practitioners they can improve health at the population level. A quick search on the PubMed for “precision public health” suggests the term is catching on, returning 75 articles since 2016.


Precision Medicine and Precision Public Health in the Era of Pathogen Next-Generation Sequencing
R Leguia et al, J Infectious Dis, November 2019 (Posted: Nov-24-2019 7AM)

We briefly discuss the history of NGS technologies and describe how the techniques developed during the past 40 years have impacted our understanding of infectious diseases. Beyond obvious clinical and public health applications, we also discuss the challenges that still remain within this rapidly evolving field.


Artificial intelligence for precision medicine in neurodevelopmental disorders
M Uddin et al, NPJ Digital Medicine, November 21, 2019 (Posted: Nov-22-2019 8AM)

Much hope is pinned on the opportunity to quantify risk from patterns of genomic variation, including the functional characterization of genes and variants, but this ambition is confounded by phenotypic and etiologic heterogeneity, along with the rare and variable penetrant nature of the underlying risk variants identified.


Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations
C Hu et al, JCO Precision Oncology, October 2019 (Posted: Nov-22-2019 8AM)

Here we provide a concise overview of design options for both the setting of single-biomarker/single-disease and the setting of multiple-biomarker/multiple-disease types. We focus on explaining the trial design and practical considerations and rationale of when to use which designs, as well as how to incorporate various adaptive design components.


In Precision Medicine, ‘We Need Dialogue Across Disciplines’
Boston University School of Public Health, November 2019 (Posted: Nov-20-2019 9AM)

Precision medicine is often reduced to being all about genetics, but I think that’s a misread on how it was originally conceived. When I think about the promise of precision, it’s the ability to harness tools in a wide variety of research activities that will improve the way we deliver care in the clinical setting, and the way we think about population health.


Qualifying and quantifying the precision medicine rhetoric.
Lee Jasmine et al. BMC genomics 2019 Nov 20(1) 868 (Posted: Nov-20-2019 8AM)

To our knowledge, this is the first study to map and qualify the global precision medicine landscape. Our findings reveal that precision medicine efforts range from large model cohort studies involving multidimensional, longitudinal data to biorepositories with a collection of blood samples.


Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer
H Sarvas et al, JNCI, November 2019 (Posted: Nov-17-2019 7AM)

Precision medicine offers opportunities for reducing the costs, burdens, and time associated with drug development. We examined time, number of trials, indications tested and patient burden needed to achieve first FDA license for all 5 novel anti-cancer precision-medicine drugs and all 10 novel non-precision medicine drugs receiving FDA approval 2010-2014


Advancing Personalized Medicine Through Prediction
AR Localio et al, Annals of Internal Medicine, November 12, 2019 (Posted: Nov-13-2019 8AM)


The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement
DM Kent et al, Annals of Internal Medicine (Posted: Nov-13-2019 8AM)

The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement was developed using a multidisciplinary technical expert panel, targeted literature reviews, simulations to characterize potential problems with predictive approaches, and a deliberative process engaging the expert panel.


Precision medicine: The future of diagnostic approach to pulmonary hypertension?
Kedzierski Piotr et al. Anatolian journal of cardiology 2019 Sep (4) 168-171 (Posted: Nov-06-2019 9AM)


Cancer researchers embrace AI to accelerate development of precision medicine
J Roach, the AI Blog, October 27, 2019 (Posted: Oct-29-2019 9AM)

Biomedical researchers are embracing artificial intelligence to accelerate the implementation of cancer treatments that target patients’ specific genomic profiles. To harness this potential, researchers developed the Clinical Knowledgebase, or CKB, is a searchable database where subject matter experts store, sort and interpret complex genomic data.


Vision of the Future of Medical Science
Francis Collins, Time, October 25, 2019 (Posted: Oct-27-2019 11AM)

Among the many efforts now poised to change the future of health are those to harness the power of gene editing, expand the reach of cancer immunotherapy, map the human brain and build a solid foundation for a more individualized approach to health care, often called precision medicine.


New Case Detection by Cascade Testing in Familial Hypercholesterolemia: A Systematic Review of the Literature.
Lee Christopher et al. Circulation. Genomic and precision medicine 2019 Oct (Posted: Oct-24-2019 8AM)

We conducted a systematic review of published studies of cascade testing for FH which reported number of index cases and number of relatives tested and specified methods of contacting relatives and testing modalities methods utilized. For each study we calculated yield (proportion of relatives who test positive) and new cases per index case.


One Little Girl’s Story Highlights the Promise of Precision Medicine
F Collins, NIH director's blog, October 23, 2019 Brand (Posted: Oct-24-2019 8AM)

No treatment existed for Mila’s condition. So, in an effort to meet that urgent need, Timothy Yu and his colleagues at Boston Children’s Hospital set forth on a bold and unprecedented course of action. In less than a year, they designed a drug that targeted Mila’s unique mutation.


Enhancing Observational Data Collection to Inform Precision Cancer Research and Care
DCCPS, NCI, October 2019 Brand (Posted: Oct-22-2019 11AM)

DCCPS supports research in surveillance, epidemiology, health care delivery, behavioral science, and cancer survivorship. It is a source of expertise and evidence on issues such as the quality of cancer care, the economic burden of cancer, geographic information systems, statistical methods, communication, behavioral research and health care delivery.


NIH’s All of Us Partners with HudsonAlpha on Long-Read Sequencing Project
Clinical Omics, October 18, 2019 (Posted: Oct-21-2019 10AM)

The NIH’s All of Us Research Program will assess the use of DNA sequencing technologies for diagnosis and treatment of common and rare diseases. The project will use long-read whole genome sequencing technologies to generate genetic data on about 6,000 samples from participants of different backgrounds.


Integration of Large-Scale Genomic Data Sources With Evolutionary History Reveals Novel Genetic Loci for Congenital Heart Disease
E Fotieu et al, Circulation Genomics and Precision Medicine, October 2019 (Posted: Oct-19-2019 7AM)

We compared copy number variants present in 4634 nonsyndromic CHD cases derived from publicly available data resources and the literature, and >27?000 healthy individuals. We analyzed deletions and duplications independently and identified copy number variant regions exclusive to cases. These data were integrated with whole-exome sequencing data.


A systems approach to clinical oncology uses deep phenotyping to deliver personalized care
JT Yurkovich et al, Nature Rev Oncology, October 2019 (Posted: Oct-19-2019 7AM)


Understanding Precision Medicine And AI Within The Life Cycle Of Technology Revolutions
D Shaywitz, Forbes, October 16, 2019 (Posted: Oct-17-2019 9AM)


Precision medicine in pancreatic cancer: treating every patient as an exception.
Herbst Brian et al. The lancet. Gastroenterology & hepatology 2019 Oct (10) 805-810 (Posted: Oct-16-2019 6AM)

Patients with pancreatic cancer have not benefited from recent improvements in overall survival brought about by precision medicine in other malignancies. This failure is not due to a dearth of precision-medicine research in pancreatic ductal adenocarcinoma (PDAC), the main type of pancreatic cancer.


Microbiome research needs a gut check
T Caulfield, The Globe and Mail, October 10, 2019 (Posted: Oct-13-2019 1PM)

It happened with stem-cell research. Ditto genetics and precision medicine. And now we are seeing it play out with microbiome research. Good science is being exploited to market bunk products and ideas. Gut hype is everywhere.


New Precision Medicine Treatment Could Benefit Many Men with Treatment-Resistant Metastatic Prostate Cancer
by Andrea K. Miyahira, Prostate Cancer Foundation, October 1, 2019 (Posted: Oct-11-2019 8AM)

A new study reported positive results from a Phase 3 clinical trial testing the PARP-inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have alterations in certain DNA damage repair (DDR) genes; a result which will likely lead to a new FDA-approval. Roughly 20-30% of mCRPC patients harbor these DDR gene mutations in their tumors and thus may benefit from PARP-inhibition.


Family Health History: The First Genetic Test in Precision Medicine.
Bennett Robin L et al. The Medical clinics of North America 2019 Nov 103(6) 957-966 (Posted: Oct-09-2019 8AM)

The collection of family history has always been a tool for genetic evaluation, but it remains an essential tool even in the age of genomic medicine. Patients may have a risk for a disease based on family history regardless of the results of genetic and genomic tests.


Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant.
Neugut Y Dana et al. Annals of internal medicine 2019 Oct (Posted: Oct-09-2019 8AM)

This article discusses potential indications for genetic testing in an African American patient with chronic kidney disease who is being evaluated for a kidney transplant. Two known risk variants in the APOL1 (apolipoprotein L1) gene predispose to kidney disease and are found almost exclusively in persons of African ancestry.


Precision Public Health: One- stop shop for data and datasets for precision public health research
University of Florida Library, catalog of resources and datasets, 2019 (Posted: Oct-05-2019 8AM)

Precision medicine ushers in a new era of biomedical research and health care applications. These same technologies also guide precision public health. In a research setting Precision public health can be used to create programs and deliver interventions that are tailored to underserved community groups and improve health outcomes.


Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms
M Bachtiar et al, The Pharmacogenomics Journal, October 3, 2019 (Posted: Oct-04-2019 9AM)


The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead.
Evans William E et al. Clinical pharmacology and therapeutics 2019 Sep (Posted: Oct-02-2019 8AM)

Much has been written about the promise of "precision medicine", especially in oncology, where somatic mutations can influence the response of cancer cells to "targeted therapy". There have been successful examples of targeted therapy improving the outcome of some childhood cancers.


Will genome sequencing bring precision medicine for all?
A Anthony, The Guardian, September 28, 2019 (Posted: Sep-30-2019 8AM)

There are conditions, particularly rare diseases such as childhood developmental disorders, where genome sequencing is extremely beneficial, and may even be life-saving for some individuals. There are also conditions – many common diseases, for example – where there is currently no evidence that genome sequencing is beneficial to individuals.


Translational genomics and precision medicine: Moving from the lab to the clinic
E Zeggini et al, Science, September 27, 2019 (Posted: Sep-28-2019 8AM)

Translational genomics aims to improve human health by building on discoveries made through genetics research and applying them in the clinical setting. This progress has been made possible by technological advances in genomics and analytics and by the digital revolution.


How Public Health Can Learn From and Inform the Precision Medicine All of Us Research Program?
CDC Public Health Genomics Seminar, November 21, 2019 Brand (Posted: Sep-23-2019 8AM)

Join us to learn more about the All of Us research program, better understand how the approaches used to recruit All of Us participants can inform future public health efforts to address diversity, and share your expertise in increasing diverse participation in your own public health work.


Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network
AN Burnett-Hartmann et al, JCO Clin Cancer Informatics, September 2019 (Posted: Sep-22-2019 0PM)

Even in health care systems with sophisticated electronic health records, there were few codified data elements available for evaluating precision cancer medicine test use and results at the population level. Health care organizations should establish standards for electronic reporting of precision medicine tests.


Genetic Counseling and Public Health in the Era of Precision Medicine
MJ Khoury, CDC Blog, September 18, 2019 Brand (Posted: Sep-19-2019 9AM)

As more genetic counselors make a leap from individual patient care to population health concerns including implementation and disparities, genetic counselors will help enhance the public’s genetic awareness and literacy about genomics and family health history, contribute to policy, evaluation and implementation, and drive the overall success of genomic medicine.


Genetic underpinnings of recovery after stroke: an opportunity for gene discovery, risk stratification, and precision medicine.
Acosta Julián N et al. Genome medicine 2019 Sep (1) 58 (Posted: Sep-18-2019 9AM)


Cancer Patients Have Limited Understanding of Genomic Test Results
Health Analytics, September 2019 (Posted: Sep-18-2019 9AM)

A majority of patients with cancer don’t understand critical features of the genomic test results they receive when participating in clinical trials, according to a pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP), the first lung cancer precision medicine trial supported by the National Cancer Institute (NCI).


Seeking More Precision in Public Health
K. Bibbins-Domingo CDC Seminar, October 22 at 1 pm. Brand (Posted: Sep-16-2019 9AM)

While precision medicine has made advances in individualized patient treatments, progress at the population level requires a public health approach focused on tailored population health and prevention strategies and driven by “big data” approaches. Inclusion of diverse populations and a focus on disparities reduction are key components.


All of Us SouthEast Enrollment Center
All of Us, 2019 (Posted: Sep-14-2019 9AM)


How precision medicine and screening with big data could increase overdiagnosis
H Vogt, BMJ, September 13, 2019 (Posted: Sep-14-2019 8AM)

Precision medicine promises to improve disease prevention but entails a massive, new form of screening. The wide scope of big data screening risks increased detection of abnormalities that will never be clinically relevant. We need a clearer understanding of the natural course of multiple markers and the value of repeated measurement of markers.


Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.
Cresci Sharon et al. Circulation. Genomic and precision medicine 2019 Sep HCG0000000000000058 (Posted: Sep-13-2019 10AM)

The goals of this scientific statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.


Breast Cancer Chemoprevention—Can We Make a Case for Precision Medicine?
M Daly et al, JAMA Oncology, September 3, 2019 (Posted: Sep-04-2019 5AM)

The current USPSTF statement broadens the combinations of risk factors for clinicians to consider when recommending risk-reducing medications for breast cancer. Several new models have emerged that incorporate additional risk factors, such as breast density, menopausal status and polygenic risk scores derived from large genome-wide association studies.


Leveraging European infrastructures to access 1 million human genomes by 2022
G Saunders et al, Nature Rev Genetics, August 27, 2019 (Posted: Aug-28-2019 7AM)

Human genomics is undergoing a step change from being a predominantly research-driven activity to one driven through health care as many countries in Europe now have nascent precision medicine programs. To maximize the value of the genomic data generated, these data will need to be shared between institutions and across countries


Tandem Transplant for High-Risk Neuroblastoma-Next Steps in the Era of Precision Medicine
R Bagatell, JAMA, August 27, 2019 (Posted: Aug-28-2019 7AM)


Global Text Mining and Development of Pharmacogenomic Knowledge Resource for Precision Medicine.
Guin Debleena et al. Frontiers in pharmacology 2019 10839 (Posted: Aug-27-2019 6PM)


Precision Medicine Update: Important Progress on the Long Road from Discovery to Population Health Impact
MJ Khoury et al, CDC Blog, August 26, 2019 Brand (Posted: Aug-27-2019 7AM)

Progress in precision medicine and All of Us will continue to occur at an accelerating pace. As this project can potentially affect all of us, the public health community will continue to partner with All of Us to help reap the exciting, potential population health benefits of this effort in the decades ahead.


NIH funds genetic counseling resource ahead of million-person sequencing effort
NIH, August 2019 Brand (Posted: Aug-26-2019 9AM)

Returning results in a responsible way is integral to what precision medicine and All of Us stand for. Participants are our partners in research, who may want to receive their own health data, including genomics. The genetic counseling resource will help our participants interpret and act upon their health information.


Are Super Responders Special?
B McIntosh, Harvard Magazine, September 2019 (Posted: Aug-26-2019 9AM)

By investigating exceptional responders, we may find new paths to cancer treatment, rather than new diseases. The study has thus far recruited more than 75 participants from around the US, representing 24 different types of cancer. Many of the subjects responded exceptionally well to a conventional combination of surgery, radiation, and chemotherapy.


Clinical testing should be individualized, not based on populations
DR Walt, JCI, August 2019 (Posted: Aug-22-2019 7AM)

We can no longer rely on normal ranges for many of these new biomarkers. Each person has a healthy baseline. Their present self should be compared to their previous healthy self rather than to a population average. Variations in baseline levels will need to be understood over time.


Charting a Course: Navigating the Hype and the Hope of Precision Medicine Together
M Gaines, ASCO Connection, August 2019 (Posted: Aug-20-2019 9AM)

For oncologists and their patients on the journey to survival, precision medicine is the most promising development in decades. Yet, as with so many innovations, “the devil is in the details” and the road to precision medicine has significant hazards.


Diversifying Data: A Precision Medicine Approach to Improving Health Outcomes
K Rogers et al,. JHMP Direct, August 15, 2019 (Posted: Aug-15-2019 9AM)


Leaders of NIH’s All of Us Research Program recap progress and next steps
Strong progress has been made in efforts to advance precision medicine, NIH Research Matters, August 14, 2019 Brand (Posted: Aug-15-2019 8AM)


The “All of Us” Research Program
All of Us, NEJM, August 14, 2019 (Posted: Aug-15-2019 8AM)

The program enrolls participants 18 years of age or older from a network of more than 340 sites. The protocol includes health questionnaires, electronic health records, physical measurements, the use of digital health technology, and the collection of biospecimens. As of July 2019, >175,000 participants had contributed biospecimens.


Why should early career public health researchers pay attention to precision medicine?
C Allen, CDC Blog, August 12, 2019 Brand (Posted: Aug-12-2019 2PM)

Early career public health professionals can be leaders in evolving the field of precision public health to address challenges in health disparities and multi-level influences of health. There is a need for creativity and collaboration, which should be encouraged at the intersection of precision medicine and public health.


Dosing time matters.
Ruben Marc D et al. Science (New York, N.Y.) 2019 Aug (6453) 547-549 (Posted: Aug-12-2019 8AM)


Fried and Baccarelli Comment on Precision Public Health
LP Fried et al, AJPH, August 7, 2019 (Posted: Aug-09-2019 8AM)

We were delighted to read the article of Allen et al. published in this issue of AJPH. It is uplifting to see a group of early career investigators present their views on the ongoing dialectic on precision medicine and its role in public health.


Perspectives From Early Career Investigators Who Are “Staying in the Game” of Precision Public Health Research
CG Allen et al, AJPH, August 7, 2019 (Posted: Aug-09-2019 8AM)

Recent high-profile conversations have situated precision medicine and population health in opposition.1–3 Although the dialogue about these two fields is varied, the polarizing features of debate suggest that the central question is whether precision approaches should have a place in advancing population health efforts.


Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.
Yamazaki Yu et al. Nature reviews. Neurology 2019 Jul (Posted: Aug-08-2019 8AM)

The paper review the recent progress in clinical and basic research into the role of APOE in Alzheimer's disease pathogenesis. The authors also discuss how APOE can be targeted for AD therapy using a precision medicine approach.


Tackling Epilepsy With High-definition Precision Medicine: A Review.
Kearney Hugh et al. JAMA neurology 2019 Aug (Posted: Aug-07-2019 7AM)

High-definition medicine will require the development of analytical techniques, including artificial intelligence, that use and combine behavioral, environmental, molecular genomic, chronotype, and microbiomic data to offer the best individualized therapeutic options for disease management in each person with epilepsy.


Early career investigators and precision public health
CG Allen et al, The Lancet, August 3, 2019 (Posted: Aug-05-2019 9AM)

Skeptics of precision public health suggest that focusing on precision medicine could overshadow the true mission of public health. The authors believe opportunities are abundant to embrace the complexity of health and foster collaboration. There is a need for both precision and population health strategies when the priority is to improve health


UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety
Clinical Omics, August 2, 2019 (Posted: Aug-05-2019 8AM)


Precision Medicine Advances in HR+/HER2- Breast Cancer
K Rosa, Onc Live, July 30, 2019 (Posted: Aug-01-2019 9AM)


Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.
Tsimberidou Apostolia M et al. Cancer journal (Sudbury, Mass.) 25(4) 296-299 (Posted: Jul-31-2019 8AM)


Introduction by the Guest Editor: Oncologic Precision Medicine and the Use of Basket and Umbrella Clinical Trials.
Doroshow James H et al. Cancer journal (Sudbury, Mass.) 25(4) 243-244 (Posted: Jul-31-2019 8AM)


Mistrust And Lack Of Genetic Diversity Slow Gains In Precision Medicine
P Huang, NPR, July 25, 2019 (Posted: Jul-28-2019 4PM)

While the goal of precision medicine is to help everybody, the current research available has a major flaw. It's largely based on the genes of people who are predominantly of white and European descent.


Genetic risk scores for diabetes diagnosis and precision medicine.
Udler Miriam S et al. Endocrine reviews 2019 Jul (Posted: Jul-24-2019 9AM)


Webinar: All of Us Research Program – Reaching Communities
NACCO, webinar, August 13, 2019 (Posted: Jul-23-2019 8AM)


Precision Medicine for Cancer Care Costs a Fortune but Could Save Money in the Long Run
M Caligiuri, Newsweek, July 16, 2019 (Posted: Jul-22-2019 8AM)


Making precision medicine personal for cystic fibrosis
C Manfredi et al, Science, July 19, 2019 (Posted: Jul-19-2019 1PM)

On the basis of classifying CFTR mutant proteins, cystic fibrosis has been viewed as a model for personalized therapeutics. However, CFTR variants may have pleiotropic effects, which complicates assignment of specifically tailored drugs to discrete mechanisms In addition, the cost of new CFTR modulators constrains reimbursement and has delayed drug availability for certain patient groups


Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation
A Mamun et al, Ethnicity and Disease, July 2019 (Posted: Jul-19-2019 8AM)

The highlights of a conference that include the potential appli­cation of precision medicine at the popula­tion level, the effects of precision medicine and direct-to-consumer testing on health disparities, genetic basis of health dispari­ties, pharmacogenomics, and strategies to enhance participation of under-represented populations in precision medicine.


more


Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP